LACRISERT® Efficacy Data
The following data demonstrate the efficacy of LACRISERT® in treating Dry Eye:
8 Out of 10 Dry Eye Patients Preferred LACRISERT® to Artificial Tears1
LACRISERT® Significantly Improves the Signs of Dry Eye Better Than Artificial Tears*1
Dry Eye occurs as a result of tear film instability, which can leave the ocular surface exposed and unprotected. In a 4-week crossover study, patients who used LACRISERT® once daily experienced significant improvement of the tear film versus patients who used artificial tear drops 4 times a day, as demonstrated by rose bengal staining.*1
*All objective signs were ranked on a scale from 0 to 4, ranging from absent to mild, moderate, severe, or extreme. There was no significant difference on the measure of visual acuity between LACRISERT® and artificial tear treatments. Patients were divided into 2 treatment groups in a randomized fashion.1
LACRISERT® Significantly Improves Dry Eye Symptoms Better Than Artificial Tears†1
In a 4-week crossover study, symptoms were significantly improved in patients administering LACRISERT® once daily versus patients administering artificial tears 4 times a day. LACRISERT® patients experienced less burning, foreign body sensation, itching, smarting, soreness, and dryness.†1
†All subjective symptoms were ranked on a scale from 0 to 4, ranging from absent to mild, moderate, severe, or extreme. There was no significant difference on the measure of blurred vision, tearing, and photophobia between LACRISERT® and artificial tear treatments. Patients were divided into 2 treatment groups in a randomized fashion.1
Dry Eye Symptoms Improve Significantly With Long-term Treatment With LACRISERT®‡2
A 52-week study showed that patients’ symptoms were increasingly less severe with continued use of LACRISERT®. Patients saw greatest benefit by 6 to 9 weeks of use.‡2
‡All subjective symptoms were ranked on a scale from 0 to 4, ranging from no involvement to severe involvement.2
LACRISERT® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.
Important Safety Information
Do not use LACRISERT® if you are allergic to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT® should be carefully followed. If improperly placed, LACRISERT® may result in a scratch to the cornea of your eye. Because LACRISERT® may cause temporary blurred vision, please use caution when driving or operating machinery. Rubbing the eye(s) containing LACRISERT® should be avoided. You should always discuss this safety information with your doctor. The following adverse reactions have been reported but were in most instances mild and temporary: temporary blurring of vision, eye discomfort or irritation, matting or stickiness of eyelashes, increased sensitivity to light, eyelid swelling, and eye redness. Talk to your doctor if you have side effects that bother you or that do not go away. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
References: 1. Katz, JI, Kaufman HE, Breslin C, Katz IM. Slow-release artificial tears and the treatment of keratitis sicca. Ophthalmology. 1978;85(8):787-793. 2. Werblin TP, Rheinstrom SD, Kaufman HE. The use of slow-release artificial tears in the long-term management of keratitis sicca. Ophthalmology. 1981;88(1):78-81.
